Supplemental Figure 1

10
Supplemental Figure 1

TAGS:

description

Supplemental Figure 1. Supplemental Figure 2. Supplemental Figure 3. A. B. C. D. Supplemental Figure 4. A. B. 231. 231. C. D. 231-Ecad. 231-Ecad. E. F. 231-shEcad. 231-shEcad. G. H. DU-145. DU-145. Supplemental Figure 5. Supplemental Figure 6. Supplemental Figure 7. A. - PowerPoint PPT Presentation

Transcript of Supplemental Figure 1

Page 1: Supplemental Figure 1

Supplemental Figure 1

Page 2: Supplemental Figure 1

Supplemental Figure 2

Page 3: Supplemental Figure 1

0

20

40

60

80

100

120

140

0 0.01 0.1 1 10 100Dose Taxol (uM)

% Cell Survival

231231-EcadMCF7MCF7-shEcad

0

20

40

60

80

100

120

140

0 0.01 0.1 1 10 100Dose 5-FU (ug/ml)

% Cell Survival

231231-EcadMCF7MCF7-shEcad

020406080

100120140160

0 0.01 0.1 1 100 1000Dose Doxorubicin (nM)

% Cell Survival

231231-EcadMCF7MCF7-shEcad

020406080

100120140160

0 0.01 0.1 1 100 1000Dose Cyclophosphamide (uM)

% Cell Survival

231231-EcadMCF7MCF7-shEcad

Supplemental Figure 3

A B

C D

Page 4: Supplemental Figure 1

Supplemental Figure 4

HG

A B231 231

C D231-Ecad 231-Ecad

FE 231-shEcad 231-shEcad

DU-145 DU-145

Page 5: Supplemental Figure 1

Supplemental Figure 5

Page 6: Supplemental Figure 1

Supplemental Figure 6

Page 7: Supplemental Figure 1

Supplemental Figure 7

A

B

**

*

* *

Page 8: Supplemental Figure 1

Supplemental Figure 8

ASt

auro

spor

ine

Cam

ptot

heci

n

10nM

1000

nM10

μM10

0μM

231 231-Ecad 231-shEcadun

trea

ted

B

* *

* *

* *

untreated 1000nMStaurosporine10nM 100μM

Camptothecin10 μM

Page 9: Supplemental Figure 1

Supplemental Figure 9

DU-145

d1 d6 d1 d6 d1 d6trans

DU-145 + human heps

direct

DU-145 only

d1 d6 d1 d6 d1 d6

DU-145 + fibro

Fibro only

A

B

C

D

DU-145 only

d1 d6 d1 d6 d1 d6

DU-145 + hu heps

Hu heps only

DU-145

d1 d6 d1 d6 d1 d6siEcad

DU-145 + human heps

siControl

Page 10: Supplemental Figure 1

Supplemental Figure 10


Collected Supplemental Figures Marginsgenesdev.cshlp.org/content/suppl/2007/10/01/21.19.2448.DC1/... · Supplemental Figure 2 Supplemental Figure 4 Supplemental Figure 5 Supplemental

Collected Supplemental Figures Marginsgenesdev.cshlp.org/content/suppl/2007/10/01/21.19.2448.DC1/... · Supplemental Figure 2 Supplemental Figure 4 Supplemental Figure 5 Supplemental

Supplemental Figure 1

Supplemental Figure 1

BolteusBordey Supplemental Figure 1

BolteusBordey Supplemental Figure 1

Supplemental Figure 7(1) p u t SUPPLEMENTAL FIGURE 2 A B H3K4me3 loci Title Supplemental Figure 7(1).ai Created Date 20161030123200Z ...

Supplemental Figure 7(1) p u t SUPPLEMENTAL FIGURE 2 A B H3K4me3 loci Title Supplemental Figure 7(1).ai Created Date 20161030123200Z ...

Supplemental Information Recruitment of UBPY and ESCRT ...Supplemental Movie 2, related to Figure 1(available online) Supplemental Movie 3, related to Figure 1(available online) Supplemental

Supplemental Information Recruitment of UBPY and ESCRT ...Supplemental Movie 2, related to Figure 1(available online) Supplemental Movie 3, related to Figure 1(available online) Supplemental

Supplemental Figure Legend Supplemental Figure 1 A · Supplemental Figure Legend Supplemental Figure 1 (A) Principal component analysis of gene expression of Panc-1 and BxPC3 cells.All

Supplemental Figure Legend Supplemental Figure 1 A · Supplemental Figure Legend Supplemental Figure 1 (A) Principal component analysis of gene expression of Panc-1 and BxPC3 cells.All

SUPPLEMENTAL FIGURE LEGEND - Weeblydimitrovagen677s09.weebly.com/uploads/1/7/2/1/...1 SUPPLEMENTAL FIGURE LEGEND Supplemental Figure 1. Absence of cardiac developmental abnormalities

SUPPLEMENTAL FIGURE LEGEND - Weeblydimitrovagen677s09.weebly.com/uploads/1/7/2/1/...1 SUPPLEMENTAL FIGURE LEGEND Supplemental Figure 1. Absence of cardiac developmental abnormalities

SUPPLEMENTAL FIGURE LEGENDS Supplemental Figure 1 (A,B) (C ...dm5migu4zj3pb.cloudfront.net/manuscripts/65000/65899/JCI65899sd.pdf · Supplemental Figure 1 Siglec-7 and -9 ligand expression

SUPPLEMENTAL FIGURE LEGENDS Supplemental Figure 1 (A,B) (C ...dm5migu4zj3pb.cloudfront.net/manuscripts/65000/65899/JCI65899sd.pdf · Supplemental Figure 1 Siglec-7 and -9 ligand expression

Supplemental Figure 1.

Supplemental Figure 1.

Figure legends: Supplemental Figure 1 A) TAA;

Figure legends: Supplemental Figure 1 A) TAA;

Supplemental Digital Content Supplemental Figure 1 ...

Supplemental Digital Content Supplemental Figure 1 ...

Supplemental data: Supplemental Figure 1. Sequence of ...

Supplemental data: Supplemental Figure 1. Sequence of ...

Supplemental Figure Legend Supplemental Figure 1 ... · Supplemental Figure 4. Recombinant factors needed to be applied in cocktail form to achieve nuclear translocation. Nuclear

Supplemental Figure Legend Supplemental Figure 1 ... · Supplemental Figure 4. Recombinant factors needed to be applied in cocktail form to achieve nuclear translocation. Nuclear

Supplemental Material Supplemental Figure 1. Further Analysis of … · 2013-04-17 · ! 1! Supplemental Material Supplemental Figure 1. Further Analysis of CX3CR1 Expressing Myeloid

Supplemental Material Supplemental Figure 1. Further Analysis of … · 2013-04-17 · ! 1! Supplemental Material Supplemental Figure 1. Further Analysis of CX3CR1 Expressing Myeloid

Supplemental Figure 1 A. · Supplemental Figure 1 A. B. Let-7 target site C. miR-103/107 target site . 2 Supplemental Figure 2 . 3 Supplemental Figure 3 . 4 Supplemental Figure 4

Supplemental Figure 1 A. · Supplemental Figure 1 A. B. Let-7 target site C. miR-103/107 target site . 2 Supplemental Figure 2 . 3 Supplemental Figure 3 . 4 Supplemental Figure 4

Supplemental Figure 1 - Journal of CancerSupplemental Figure 2 . Supplemental Figure 3 . Supplemental Table 1. Relationship between CD4 TIL expression and various patient characteristics

Supplemental Figure 1 - Journal of CancerSupplemental Figure 2 . Supplemental Figure 3 . Supplemental Table 1. Relationship between CD4 TIL expression and various patient characteristics

Supplemental Figure 1 - Genes & Developmentgenesdev.cshlp.org/content/suppl/2013/11/01/27.21... · Supplemental Figure 1 Supplemental Fig. 1. (A) The binding avidity between Fz4-FcH6

Supplemental Figure 1 - Genes & Developmentgenesdev.cshlp.org/content/suppl/2013/11/01/27.21... · Supplemental Figure 1 Supplemental Fig. 1. (A) The binding avidity between Fz4-FcH6

Supplemental Figure 1.

Supplemental Figure 1.

Supplemental Figure Legends: Supplemental Figure 1 ...dm5migu4zj3pb.cloudfront.net/manuscripts/59000/59743/JCI...31 Supplemental Figure Legends: Supplemental Figure 1. Caerulein treatment

Supplemental Figure Legends: Supplemental Figure 1 ...dm5migu4zj3pb.cloudfront.net/manuscripts/59000/59743/JCI...31 Supplemental Figure Legends: Supplemental Figure 1. Caerulein treatment

Supplemental Figure 1 NADH - … · Supplemental Figure 1 ... SOD-inhibitable chemiluminescence (RLU) 0 4000 6000 2000 8000 ... Supplemental Figure 5 A. Protein levels of NOX4, FYN,

Supplemental Figure 1 NADH - … · Supplemental Figure 1 ... SOD-inhibitable chemiluminescence (RLU) 0 4000 6000 2000 8000 ... Supplemental Figure 5 A. Protein levels of NOX4, FYN,